New Funding Secured for HEALEY ALS Platform Trial
Filed with ASX · · 11 pages · English
• Firm commitments to raise ~$7.1 million from existing shareholders and new sophisticated and professional investors via a placement at $0.08 per Share – includes commitments from Directors and Management totalling ~$0.8 million (subject to shareholder approval), demonstrating strong alignment with shareholders and confidence in the Company’s strategy • 2-for-5 pro rata non-renounceable entitleme
Neurizon Therapeutics Limited on 6ix
In the deck
Story so far
Earlier from Neurizon Therapeutics
- Equity Raising Presentation
- Trading Halt
- FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial
- Neurizon Completes GMP Tablet Registration Batches
- Elanco executive appointed as Neurizon's Board Observer
Later from Neurizon Therapeutics
- Regulatory and Development Update
- Global Trademark Protection Secured Across Key Markets
- Neurizon Completes Entitlement Offer
- Neurizon secures $6million R&D Tax Incentive Rebate
- Appendix 4C & Quarterly Update
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics